[1]郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏.新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析[J].心血管病学进展,2020,(4):414-418.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
 GUO Qilong,LU Yanmei,ZHANG Ling,et al.Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study[J].Advances in Cardiovascular Diseases,2020,(4):414-418.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.021]
点击复制

新疆地区老年慢性心力衰竭住院患者的病因、合并症及药物治疗的多中心回顾性分析()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年4期
页码:
414-418
栏目:
论著
出版日期:
2020-04-25

文章信息/Info

Title:
Etiology, Comorbidity and Drug Treatment of Elderly Inpatients with Chronic Heart Failure in Xinjiang: A Multi-center Retrospective Study
作者:
郭岐龙 芦颜美 张玲 张疆华 邢强 祖克拉·吐尔洪 李耀东 周贤惠 汤宝鹏
(新疆医科大学第一附属医院心脏中心,新疆 乌鲁木齐 830054)
Author(s):
GUO Qilong LU Yanmei ZHANG Ling ZHANG Jianghua XING Qiang Zukela·Tuerhong LI  Yaodong ZHOU Xianhui TANG Baopeng
(Heart Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054 , Xinjiang, China)
关键词:
慢性心力衰竭老年患者合并症药物治疗
Keywords:
Chronic heart failure Elderly patients Comorbidity Drug treatment
DOI:
10.16806/j.cnki.issn.1004-3934.2020.04.021
摘要:
目的 调查新疆地区老年慢性心力衰竭(心衰)住院患者的常见病因、合并症特点及药物治疗情况,为新疆地区老年慢性心衰患者规范化防治提供科学依据。方法 采用多中心回顾性横断面调查研究方法,选择2018年1月——10月新疆地区13家医院共1 493例慢性心衰住院患者纳入本研究。根据患者年龄,分为普通老年组、老老年组,比较两组心衰患者的临床特点、病因、非心血管系统合并症、改善心衰预后的药物使用情况。结果 普通老年组和老老年组性别、心功能分级差异无统计学意义( P>0.05)。老老年组射血分数保留性心衰比例高于普通老年组、射血分数降低性心衰比例低于普通老年组,差异有统计学意义(P<0.05)。高血压、冠心病是两组最常见的心衰病因,老老年组平均病因数量、非心血管系统合并症数量均高于普通老年组[(1.95±0.71)vs(1.70±0.58)、(1.89±0.89)vs(1.55±0.71),P均<0.05]。老老年组心房颤动、心脏瓣膜病、脑血管疾病、外周血管病、肾功能不全、慢性贫血比例高于普通老年组,而冠心病、糖尿病比例低于普通老年组,差异均有统计学意义(P<0.05)。老老年组出院带药中血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂/血管紧张素受体脑啡肽酶抑制剂、β受体阻滞剂、醛固酮拮抗剂使用率均低于普通老年组[(65.9% vs 76.7%、51.0% vs 70.8%、62.7% vs 69.4%,P均<0.05)。结论 新疆地区老年慢性心衰患者存在多心血管病因、合并多种疾病的特点,老老年患者合并症更多、抗心衰药物应用比例较低。
Abstract:
Objective To investigate the characteristics of etiology, non-cardiovascular comorbidity and drug treatment of elderly patients with chronic heart failure (CHF) in Xinjiang, and to provide scientific evidence for prevention and treatment of elderly patients with CHF. Methods This is a multicenter retrospective cross-sectional study. a total of 1 493 inpatients with CHF from 13 hospitals in Xinjiang from January to October 2018 were investigated. Participants were classified into the general elderly group and the old elderly group according to the age of the patients. The clinical characteristics, etiology, non-cardiovascular system comorbidity and drug use to improve the prognosis of heart failure were compared between the two groups. Results There was no significant difference in gender and cardiac function between two groups ( P>0.05). The proportion of HFpEF in the old elderly group was higher than that in the general elderly group, and the proportion of HFrEF was lower (P<0.05). Hypertension and coronary heart disease are the most common causes of CHF in both groups. The average number of cardiovascular etiologic factors and non-cardiovascular comorbidities in the old elderly group was higher than that in the general elderly group [(1.95±0.71) vs (1.70±0.58) and (1.89±0.89) vs (1.55±0.71), P < 0.05 ]. The proportion of old elderly patients with atrial fibrillation, chronic heart valvular disease, cerebrovascular disease, peripheral vascular disease, renal insufficiency and anemia was higher than that of the general elderly group, while the proportion with coronary heart disease and diabetes was lower (P<0.05). The usage rates of ACEI/ARB/ARNI, beta-blocker and aldosterone antagonist in the old elderly group were lower than those in the general elderly group (65.9% vs 76.7%, 51.0% vs 70.8% and 62.7% vs 69.4%, P<0.05). Conclusion The elderly patients with CHF in Xinjiang have the characteristics of multiple causes and co-morbidity. Old elderly patients have more complications and lower proportion of anti-heart failure drugs use.

参考文献/References:


[1] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心力衰竭和心肌病杂志(中英文),2018,2(4):196-225.

[2] Ziaeian B,Fonarow GC. Epidemiology and aetiology of heart failure[J]. Nat Rev Cardiol,2016,13(6):368-378.

[3] Mozaffarian D,Benjamin EJ,Go AS,et al. Heart disease and stroke statistics-2016 update:a report from the american heart association[J]. Circulation,2016,133(4):e38-360.

[4] 谭漪扬,周建中. 慢性心力衰竭治疗新进展—LCZ696[J]. 心血管病学进展,2016(1):42-45.

[5] Dharmarajan K,Rich MW. Epidemiology,pathophysiology,and prognosis of heart failure in older adults[J]. Heart Fail Clin,2017,13(3):417-426

[6] 周京敏,崔晓通,葛均波. 中国心力衰竭的流行病学概况[J]. 中华心血管病杂志,2015,43(12):1018-1021.

[7] 李琳,莫卿,莫婷,等. 老年慢性心力衰竭患者临床特征和药物治疗状况多中心回顾性分析[J]. 中华医学杂志,2018,98(9):673-677.

[8] Gurwitz JH,Magid DJ,Smith DH,et al. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction[J]. Am J Med,2013,126(5):393-400.

[9] 李慧,齐国先. 老年射血分数保留的心功能不全研究进展[J]. 心血管病学进展,2016,37(4):354-357.

[10] Chioncel O,Lainscak M,Seferovic PM,et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved,mid-range and reduced ejection fraction:an analysis of the ESC Heart Failure Long-Term Registry[J]. Eur J Heart Fail,2017,19(12):1574-1585

[11] Farmakis D,Simitsis P,Bistola V,et al. Acute heart failure with mid-range left ventricular ejection fraction:clinical profile,in-hospital management,and short-term outcome[J]. Clin Res Cardiol,2017,106(5):359-368.

[12] Maggioni AP,Dahlstr?m U,Filippatos G,et al. EURObservational Research Programme:regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot)[J]. Eur J heart Fail,2013,15(7):808-817.

[13] Tavazzi L,Senni M,Metra M,et al. Multicenter prospective observational study on acute and chronic heart failure:one-year follow-up results of IN-HF (Italian Network on Heart Failure) outcome registry[J]. Circ Heart Fail,2013,6(3):473-481.

[14] Shiga T,Suzuki A,Haruta S,et al. Clinical characteristics of hospitalized heart failure patients with preserved,mid-range,and reduced ejection fractions in Japan[J]. ESC Heart Fail,2019,6(3):475-486.

[15] 周浩斌,安冬琪,詹琼,等. 不同射血分数心力衰竭患者临床特征和预后的回顾性分析[J]. 中华内科杂志,2017,56(4):253-257.

[16] 中华医学会心血管病学分会. 中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查[J]. 中华心血管病杂志,2002,30(8):450-454.

[17] Moe G. Heart failure with multiple comorbidities[J]. Curr Opin Cardiol,2016,31(2):209-216.

[18] 马金萍,黄娇红,王林. 老年慢性心力衰竭住院患者药物治疗情况分析[J]. 中华老年医学杂志,2010,29(9):732-737.

[19] Zhang Y,Zhang J,Butler J,et al. Contemporary epidemiology,management,and outcomes of patients hospitalized for heart failure in China:results from the China Heart Failure (China-HF) registry[J]. J Card Fail,2017,23(12):868-875

[20] von Scheidt W,Zugck C,Pauschinger M,et al. Characteristics,management modalities and outcome in chronic systolic heart failure patients treated in tertiary care centers:results from the EVIdence based TreAtment in Heart Failure (EVITA-HF) registry[J]. Clin Res Cardiol,2014,103(12):1006-1014.

相似文献/References:

[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
 DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(4):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
 ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(4):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
 YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(4):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[4]田晶,张青,张岩波,等.慢性心力衰竭结局评价指标研究进展[J].心血管病学进展,2019,(6):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
 TIAN Jing,ZHANG qing,ZHANG Yanbo,et al.Outcome Indicators for Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2019,(4):931.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.023]
[5]胡威,苏芳菊,张卫泽.左室四极导线在心脏再同步化治疗中的应用进展[J].心血管病学进展,2020,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
 HU Wei,SU Fangju,ZHANG Weize.Application of Left Ventricular Quadrupole in Cardiac Resynchronization Therapy[J].Advances in Cardiovascular Diseases,2020,(4):268.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.013]
[6]毛玉琳 何胜虎.2型糖尿病和慢性心力衰竭[J].心血管病学进展,2020,(5):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
 MAO Yulin,HE Shenghu.Type 2 Diabetes Mellitus and Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(4):491.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.012]
[7]郭曦滢,孙煌,樊朝美,等.非奈利酮治疗慢性心力衰竭的研究进展[J].心血管病学进展,2020,(10):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
 GUO XiyingSUN HuangFAN ChaomeiZHANG Jian.Finerenone in the Treatment of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2020,(4):1021.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.006]
[8]吴燕婷 李萍 吴寒.慢性心力衰竭再住院率研究进展[J].心血管病学进展,2021,(8):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
 WU Yanting,LI Ping,WU Han.Rehospitalization Rate of Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2021,(4):691.[doi:10.16806/j.cnki.issn.1004-3934-2021.08.005]
[9]陈晓梅 陈巧玮 曾纪娟 张庆.可穿戴设备在慢性心力衰竭患者管理中的应用进展[J].心血管病学进展,2023,(3):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
 CHEN Xiaomei,CHEN Qiaowei,ZENG Jijuan,et al.Application of Wearable Devices in Management of Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(4):233.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.010]
[10]李彤 呼海娟 崔炜.慢性心力衰竭患者脑钠肽抵抗机制的研究进展[J].心血管病学进展,2023,(3):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]
 LI Tong,HU Haijuan,CUI Wei.Mechanism of Brain Natriuretic Peptide Tolerance in Patients with Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2023,(4):238.[doi:10.16806/j.cnki.issn.1004-3934.2023.03.011]

备注/Memo

备注/Memo:
基金项目:国家重点研发计划(2016YFC0900905)
通讯作者:汤宝鹏,E-mail: tangbaopeng1111@163.com

收稿日期:2019-10-22 

更新日期/Last Update: 2020-07-29